Keywords
Cystic fibrosis
Lung cancer
Lung disease
Abstract
As with other fields, respiratory medicine has seen several significant advancements in recent years. The current status and prospects of certain noteworthy ones are presented.
References
Edmondson C, Davies JC. . Therapeutic Advances in Chronic Disease. 2016;7:170–83. Available from: https://doi.org/10.1177/2040622316641352
Massie J, Delatycki MB. Cystic Fibrosis Carrier Screening. Paediatric Respiratory Reviews. 2013;14:270–5. Available from: https://doi.org/10.1016/j.prrv.2012.12.002
Goldman LS Andrew I. Goldman-Cecil Medicine. Elsevier - Health Science; 2011.
Lawrence H, Moore T, Usmani O, Hickin S. Respiratory System. 2019.
Cystic Fibrosis Trust. Kalydeco. Available from: https://www.cysticfibrosis.org.uk/the-work-we-do/campaigning-hard/life-saving drugs/kalydeco
Fajac I, De Boeck K. New horizons for cystic fibrosis treatment. Pharmacology & Therapeutics. 2017;170:205–11. Available from: https://doi.org/10.1016/j.pharmthera.2016.11.009
Aitken ML, Bellon G, De Boeck K, et al. Long-term inhaled dry powder mannitol in cystic fibrosis: an international randomized study . Am J Respir Crit Care Med. 2012;185:645–52. Available from: https://doi.org/10.1164/rccm.201109-1666OC
Davies JC, Wainwright CE, Canny GJ, et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 Years with cystic fibrosis with a G551D mutation. Am J Respir Crit Care Med. 2013;187:1219–25. Available from: https://doi.org/10.1164/rccm.201301-0153OC
Cystic Fibrosis Trust. Orkambi. Available from: https://www.cysticfibrosis.org.uk/the-work-we-do/campaigning-hard/life-saving-drugs/orkambi
Mahase E. Cystic fibrosis: triple therapy shows promising results. BMJ. 2019;l6347. Available from: https://doi.org/10.1136/bmj.l6347
Cystic Fibrosis Trust. Triple combination therapy (Trikafta). Available from: https://www.cysticfibrosis.org.uk/the-work-we-do/campaigning-hard/life-saving-drugs/triple-combination-therapy
De Boeck K, Davies JC. Where are we with transformational therapies for patients with cystic fibrosis? Current Opinion in Pharmacology. 2017;34:70–5. Available from: https://doi.org/10.1016/j.coph.2017.09.005
NHS England. NHS England concludes wide-ranging deal for cystic fibrosis drugs. Available from: https://www.england.nhs.uk/2019/10/nhs-england-concludeswide-ranging-deal-for-cystic-fibrosis-drugs/
Suresh K, Naidoo J, Lin CT, Danoff S. Immune checkpoint immunotherapy for non-small cell lung cancer. Chest.2018;154:1416–23. Available from: https://doi.org/10.1016/j.chest.2018.08.1048
Brahmer JR, Tykodi SS, Chow LQM, et al. Safety and activity of Anti–PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366:2455–65. Available from: https://doi.org/10.1056/NEJMoa1200694
Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus Docetaxel in advanced nonsquamous non–small-cell lung cancer. N Engl JMed. 2015;373:1627–39. Available from: https://doi.org/10.1056/NEJMoa1507643
Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer. N Engl J Med. 2016;375:1823–33. Available from: https://doi.org/10.1056/NEJMoa1606774
Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer. N Engl J Med. 2017;377:1919–29. Available from: https://doi.org/10.1056/NEJMoa1709937
Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined Nivolumab and Ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373:23–34. Available from: https://doi.org/10.1056/NEJMc1509660
Nishino M, Giobbie-Hurder A, Hatabu H, Ramaiya NH, Hodi FS. Incidence of programmed cell death 1 inhibitor–related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis. JAMA Oncol. 2016;2:1607. Available from: https://doi.org/10.1001/jamaoncol.2016.2453
Naidoo J, Wang X, Woo KM, et al. Pneumonitis in patients treated with anti–programmed death-1/programmed death ligand 1 therapy. JCO. 2017;35:709–17. Available from: https://doi.org/10.1200/JCO.2016.68.2005
Voong KR, Hazell S, Hu C, et al. MA 09.08 Receipt of chest radiation and immune-related pneumonitis in patients with NSCLC treated with Anti-PD-1/PD-L1. Journal of Thoracic Oncology. 2017;12:S1837. Available from: https://doi.org/10.1016/j.jtho.2017.09.529
Haanen J, Carbonnel F, Robert C, et al. Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 2017;28:iv119–42. Available from: https://doi.org/10.1093/annonc/mdx225
Kolb M, Vašáková M. The natural history of progressive fibrosing interstitial lung diseases. Respir Res. 2019;20:57. Available from: https://doi.org/10.1186/s12931-019-1022-1
Cottin V, Hirani NA, Hotchkin DL, et al. Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases. Eur Respir Rev. 2018;27:180076. Available from: https://doi.org/10.1183/16000617.0076-2018
Boehringer Ingelheim. INBUILD® meets primary endpoint– study evaluated nintedanib in patients across a range of progressive fibrosing interstitial lung diseases. 2019. Available from: https://www.boehringer-ingelheim.com/pressrelease/
Flaherty KR, Brown KK, Wells AU, et al. Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease. BMJ Open Resp Res. 2017;4:e000212. Available from: https://doi.org/10.1136/bmjresp-2017-000212